- VeriSIM Life introduces AtlasGEN™ Novel Drug Designer, merging AI-driven chemical exploration with biological validation.
- Unlike traditional AI tools, AtlasGEN considers biological translation, enhancing drug candidate selection efficiency and reducing research costs.
- The platform features BIOiSIM®, incorporating the Translational Index™ for evaluating therapeutic efficacy, fostering transparency in AI-designed drugs.
- AtlasGEN addresses critical challenges in drug development, including increasing costs, declining success rates, and patient treatment gaps.
- Dr. Jascha Blobel emphasizes the importance of integrating generative AI with bio knowledge systems for future drug design endeavors.
Main AI News:
VeriSIM Life, a pioneer in AI-driven R&D solutions for revolutionary drug development, has introduced the latest innovation: AtlasGEN™ Novel Drug Designer. AtlasGEN stands out as the premier platform merging generative chemical exploration with biological authentication, revolutionizing drug candidate selection by streamlining processes and slashing research expenses, all while enhancing clinical success probabilities.
Dissimilar to conventional generative AI tools for drug discovery that solely rely on chemical attributes, AtlasGEN goes a step further by incorporating biological translation. This entails assessing how effectively drugs function within the human body and their safety profile. The integration of biological translation is pivotal, considering that AI-generated novel drug compounds can be impractical for clinical use if not bound by biological constraints. Typically, identifying thousands of potential compound hits necessitates extensive experimental validation to assess clinical viability, incurring significant costs for drug developers. By pre-validating novel compound hits computationally based on biological translation, AtlasGEN substantially alleviates the experimental burden and augments the likelihood of successful drug programs.
“In an era where the pharmaceutical landscape struggles with diminishing success rates in new drug development, accompanied by escalating costs and shortages detrimental to patients, the imperative for our healthcare system is swift and efficient mechanisms for generating safe and efficacious drugs. I am enthused by the potential of AtlasGEN to address this pressing challenge,” remarked Dr. Jo Varshney, VeriSIM Life’s CEO and Founder.
AtlasGEN Novel Drug Designer is an integral component of the BIOiSIM® platform, an avant-garde decision engine facilitating drug discovery and R&D risk mitigation. Central to BIOiSIM is the Translational Index™, a distinctive amalgamation of metrics indicating a compound’s probable therapeutic efficacy, akin to a credit score. This index offers insights into the artificial intelligence analysis conducted by the platform, not only fostering the creation of innovative compounds but also elucidating the rationale behind their predicted potency and safety, thereby enhancing transparency surrounding AI-designed drugs.
The unveiling of AtlasGEN comes at a critical juncture, with over 300 million patients lacking treatments for unmet diseases and an estimated 10 million individuals succumbing to cancer this year alone, underscoring the urgency for novel therapeutic solutions. Concurrently, traditional methodologies for drug discovery have witnessed declining success rates. Despite a 72% surge in registered new drug candidates, the proportion of approved drugs from major pharmaceutical companies has plummeted from 76% to a mere 25%.
“Generative AI has sparked considerable excitement within the industry, and rightfully so,” commented Dr. Jascha Blobel, Chief Business Officer at Golden Gate Biotech. “However, AI in isolation cannot tailor drugs for real patients. I firmly advocate for a future where computational drug design harnesses the synergy of generative AI and bio knowledge systems, guiding and governing discovery endeavors. AtlasGEN holds immense promise in reshaping the pharmaceutical landscape.“
Conclusion:
VeriSIM Life’s unveiling of AtlasGEN signifies a paradigm shift in the pharmaceutical landscape. By combining AI-driven innovation with biological insights, AtlasGEN promises to streamline drug discovery processes, reduce costs, and improve clinical success rates. This disruptive technology has the potential to revolutionize the market by addressing pressing industry challenges and offering novel therapeutic solutions for unmet medical needs.
